Key result
In patients treated with digoxin fab antibodies, the FPIA-UF assay yielded a lower mean area under the concentration-time curve than BDS or EMIT.
Why the study?
Do BDS and EMIT assays provide reliable free serum digoxin concentrations compared to FPIA-UF in digoxin toxic patients treated with fab antibodies?
Observational (n=8)
Do BDS and EMIT assays provide reliable free serum digoxin concentrations compared to FPIA-UF in digoxin toxic patients treated with fab antibodies?
FPIA-UF is the preferred assay for determining free serum digoxin concentrations during digoxin fab antibody therapy due to significant bias in BDS and EMIT assays.
Answers are grounded in this paper and cite their sources.
BDS/EMIT may overestimate free digoxin AUC post-fab; this case report leaves open the optimal assay for toxicity monitoring.
Digoxin fab antibody therapy is known to interfere with digoxin immunoassays causing spurious serum digoxin concentrations. The reliability and precision of three digoxin immunoassays--Baxter Dade Stratus (BDS), Syva affinity column enzyme-mediated immunoassay (EMIT), and the reference assay Abbott TDx fluorescence polarization immunoassay following ultrafiltration (FPIA-UF)--were compared in eight digoxin toxic patients treated with digoxin fab antibodies. Five to eight blood samples were drawn serially up to 204 h post digoxin fab therapy. The serum digoxin concentration in each sample was determined by each of the three assays. The mean (+/- SD) area under the serum digoxin concentration-time curve was significantly lower for FPIA-UF than for BDS or EMIT (86.1 +/- 58.2 vs 158.1 +/- 88.6 and 176.3 +/- 115.3 h.ng/ml p less than 0.01, respectively). BDS correlated better with FPIA-UF (r2 = 0.71) than did EMIT (r2 = 0.45). Predictive performance of the BDS and EMIT assays demonstrated that the mean prediction error (bias) (0.62 vs 0.78 ng/ml) and the mean squared prediction error (precision) (0.48 vs 0.76) differed significantly from zero (p less than 0.05). However, BDS had significantly less bias and greater precision than did EMIT (p less than 0.05). In the presence of digoxin fab antibodies, BDS is a better predictor of free serum digoxin concentration than is EMIT, but both have considerable bias. Based on these results, FPIA-UF should be the assay of choice for determining free serum digoxin concentrations during fab therapy.
No takes yet. Share an insight, caveat, or question.
Ujhelyi et al. (1992) conducted an observational in Digoxin toxicity (n=8). Baxter Dade Stratus (BDS) and Syva EMIT assays vs. Abbott TDx FPIA-UF reference assay was evaluated on Area under the serum digoxin concentration-time curve (p=<0.01). In patients treated with digoxin fab antibodies, the FPIA-UF assay yielded a lower mean area under the concentration-time curve than BDS or EMIT.
Synapse has enriched 10 related papers. Consider them for comparative context: